Pfizer Inc. (NYSE:PFE) reported on Thursday topline data from two Phase 3 clinical trials assessing LITFULO as a once-daily treatment for nonsegmental vitiligo (NSV).
The trials demonstrated that the medication provided significant improvements for patients suffering from both active and stable forms of the condition across a broad range of disease severity.
Tackling NSV And Future Regulatory Filings
Nonsegmental vitiligo is a chronic autoimmune disorder where the body’s immune defenses mistakenly attack melanin-producing cells, resulting in the appearance of depigmented, white patches on the skin and hair over time.
Based on these positive outcomes, Pfizer is preparing to submit global applications to regulatory agencies. The company aims to secure approval for LITFULO as a new oral systemic therapy for adults living with NSV.
Evaluating Efficacy In Phase 3 Trials
The clinical evaluation involved two separate studies. The TRANQUILLO trial enrolled participants 12 years of age and older, whereas TRANQUILLO 2 was restricted solely to adult patients.
In both evaluations, daily doses of 50 milligrams and 100 milligrams of LITFULO yielded clinically meaningful progress over a placebo.
These improvements were measured using the Vitiligo Area Scoring Index (VASI).
By week 52, a substantially higher number of patients receiving the medication achieved at least a 75% improvement in facial vitiligo and a 50% improvement in total body vitiligo.
Proven Safety And Upcoming Milestones
The safety data observed during the vitiligo studies remained consistent with LITFULO’s established track record in alopecia areata.
No new safety signals emerged, and the proportion of treatment-emergent adverse events was similar across all groups.
The FDA previously approved LITFULO in 2023 for severe alopecia areata in adults and adolescents.
Moving forward, Pfizer plans to initiate a pivotal study for moderate alopecia areata in 2026 and will present additional vitiligo findings at a future medical conference.
Last week, Pfizer paused the distribution of its Premarin vaginal cream in India due to unspecified supply chain difficulties.
Premarin, a treatment utilizing a blend of estrogen hormones, is primarily prescribed to alleviate vaginal dryness, painful intercourse, and other conditions linked to dropping estrogen levels during menopause.
PFE Price Action: Pfizer shares were down 1.82% at $24.69 at the time of publication on Thursday, according to Benzinga Pro data.
Photo: Jonathan Weiss / Shutterstock
Login to comment